Imagion Biosystems Ltd has released a press release.
Positive Results Received from WSU on MagSense Dosage
Filed with ASX ·
6ix hasn’t read this filing yet.
Imagion Biosystems Ltd. on 6ix
Earlier from Imagion Biosystems
- Appendix 4C and Quarterly Activities Report - September 2025
- Imagion Biosystems HER2 Breast Cancer Program Update
- Ph2 Manufacturing & Imaging Optimisation Activities Commence
- Appendix 4D and Half-yearly Financial Report
- IBX Secures Firm Commitments for A$3.5m Capital Raising
Later from Imagion Biosystems
- Positive Final WSU Trial Results To Support IND Submission
- Mercer Convertible Securities Conversion and Amendment
- Appendix 4C and Quarterly Activities Report - December 2025
- IBX's IND Application Lodged with FDA for HER2 Phase 2 Trial
- Medical-imaging company Imagion Biosystems Lodges IND with FDA for Phase 2 Trial of MagSense® HER2 targeted imaging agent
Follow Imagion Biosystems into a list and get an email when it puts out news.
Follow Imagion Biosystems